Helmholtz Gemeinschaft

Search
Browse
Statistics
Feeds

Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy

Item Type:Article
Title:Effect of siponimod on retinal thickness, a marker of neurodegeneration, in participants with SPMS: Findings from the EXPAND OCT substudy
Creators Name:Vermersch, P., Gold, R., Bar-Or, A., Cree, B.A.C., Fox, R.J., Giovannoni, G., Paul, F., Wolf, S., Li, B., Mousseau, M.C., Maio-Twofoot, T., Shi, X. and Kappos, L.
Abstract:BACKGROUND: People with MS show abnormal thinning of the retinal layers, which is associated with clinical disability and brain atrophy, and is a potential surrogate marker of neurodegeneration and treatment effects. OBJECTIVE: To evaluate the utility of retinal thickness as a surrogate marker of neurodegeneration and treatment effect in participants with secondary progressive MS (SPMS) from the optical coherence tomography (OCT) substudy of the EXPAND Phase 3 clinical trial (siponimod versus placebo). METHODS: In the OCT substudy population (n=159), treatment effects on change in the average thickness of the retinal layer, peripapillary retinal nerve fiber layer (pRNFL), and combined macular ganglion cell and inner plexiform layers (GCIPL) were analyzed by high-definition spectral domain OCT at months 3, 12, and 24. RESULTS: Thinning from baseline was observed across all retinal layers and time points in the placebo group. Siponimod significantly reduced GCIPL thinning versus placebo at month 24 (adjusted mean [SE] [µm]: −0.47 [0.81] vs. −4.29 [1.23]; p=0.01), and overall retinal thinning at months 12 (+0.66 [0.54] vs. −1.86 [0.75]; p=0.006) and 24 (−0.05 [0.59] vs. −2.30 [0.88]; p=0.033). Although not significant, results for pRNFL consistently followed the same trends. CONCLUSION: This exploratory substudy supports further investigation of OCT measurement of retinal atrophy as a non-invasive potential biomarker of treatment effects on neurodegeneration in SPMS.
Keywords:Optical Coherence Tomography, Retinal Thickness, Macular Ganglion Cell and Inner Plexiform Layers, Secondary Progressive MS, Siponimod
Source:Multiple Sclerosis and Related Disorders
ISSN:2211-0348
Publisher:Elsevier
Page Range:106259
Number of Pages:1
Date:4 January 2025
Official Publication:https://doi.org/10.1016/j.msard.2025.106259

Repository Staff Only: item control page

Open Access
MDC Library